The aim of the research was to study the phenotype of eosinophils in children with atopic bronchial asthma and their role as diagnostic criteria of the disease. Materials and methods. We have examined 130 children aged from 6 to 18 years old with atopic bronchial asthma. The control group consisted of 40 healthy children from 6 to 18 years old, who didn’t have allergic diseases. During the research the relative and absolute levels of eosinophils, the level of eosinophils carrying FcεRI and FcεRII (CD23) – receptors were established. Results. The relative level of eosinophils in asthmatic children was 6.00% [3.00; 8.00], the absolute level – 417.00 cells/μL [232.00; 636,00], which is significantly higher compared to control group, where the relative level was 2.50% [1.00; 3.00%] and the absolute level was 166.50 cells/μl [86.00; 213.00] (p<0.001). The level of eosinophils carrying the FcεRI receptor was 420,00 cells/μl [250,00; 660,00], which is significantly higher than in the control group – 200,00 cells/μl [140,00; 240.00] (p<0.001). The relative level of eosinophils carrying CD23 receptor on their surface was 62.20% [35.40; 76.60] and the absolute level –223.37 cells/μl [105.30; 375.24]. The results are significantly higher than those of the control group: 25.45% [14.30; 30,60] (p<0,001), and 30,88 cells/μl [25,63; 42.84] (p <0.0001) respectively. It was found in the ROC-analysis that there is high evidence of presence of atopic bronchial asthma if absolute levels of eosinophils carrying CD23 receptor was 73.008 cells/μl or more or the relative index – 35.10% and more. Conclusions. The relative and absolute levels of eosinophils, as well as eosinophils carrying FcεRI and CD23 receptors are statistically significantly higher in atopic bronchial asthma than in control group patients. Increased number or relative index (73.008 cells/μl or ≥ 35.10% respectively) of eosinophils carrying CD 23 receptors can be considered as a diagnostic criterion of atopic bronchial asthma.

In recent years there has been growing evidence to suggest a major role of basophils alongside eosinophils and mast cells in allergic inflammation. The aim of this study was to analyze the dynamics of the basophil phenotypes after the use of magneto-la-ser therapy in children with atopic bronchial asthma. Materials and methods. A total of 66 children with mild persistent atopic bronchial asthma (aged 6 to 18 years old) were examined. Group A included 34 children who received magneto-laser therapy together with basic asthma treatment (low dose of inhaled corticosteroids). Group B included 32 children who received only basic asthma therapy. The level of CD203с + , CD203с + CD63 + , CD203с + IgE + basophils was determined in peripheral blood in the beginning of the study, after 2 weeks and after 3 months. Results. A statistically significant decrease in the absolute levels of CD203с+CD63+ and CD203с + IgE + basophils and in the relative level of CD203с + IgE + among all CD203с + basophils was determined in group A after magneto-laser therapy. The comparison of group A and group B indices revealed a significant difference between the relative level of CD203с + IgE + basophils after 12-15 days from the beginning of the study. This indicator was significantly lower in group A than in group B (p<0.05). The absolute level of CD203с + IgE + basophils was significantly lower in group A in comparison with group B after 82-90 days (p<0.05). Conclusions. Magneto-laser therapy can change the phenotype of basophils in children with atopic bronchial asthma, causing suppression of proallergic pa-rameters. Considering these results there is reason to believe, that it is possible to use this method as an additional immunocorrective treatment in patients with basophilic phenotype of atopic asthma.

In recent years there has been growing evidence to suggest a major role of basophils alongside eosinophils and mast cells in allergic inflammation. The aim of this study was to analyze the dynamics of the basophil phenotypes after the use of magneto-la-ser therapy in children with atopic bronchial asthma. Materials and methods. A total of 66 children with mild persistent atopic bronchial asthma (aged 6 to 18 years old) were examined. Group A included 34 children who received magneto-laser therapy together with basic asthma treatment (low dose of inhaled corticosteroids). Group B included 32 children who received only basic asthma therapy. The level of CD203с + , CD203с + CD63 + , CD203с + IgE + basophils was determined in peripheral blood in the beginning of the study, after 2 weeks and after 3 months. Results. A statistically significant decrease in the absolute levels of CD203с+CD63+ and CD203с + IgE + basophils and in the relative level of CD203с + IgE + among all CD203с + basophils was determined in group A after magneto-laser therapy. The comparison of group A and group B indices revealed a significant difference between the relative level of CD203с + IgE + basophils after 12-15 days from the beginning of the study. This indicator was significantly lower in group A than in group B (p<0.05). The absolute level of CD203с + IgE + basophils was significantly lower in group A in comparison with group B after 82-90 days (p<0.05). Conclusions. Magneto-laser therapy can change the phenotype of basophils in children with atopic bronchial asthma, causing suppression of proallergic pa-rameters. Considering these results there is reason to believe, that it is possible to use this method as an additional immunocorrective treatment in patients with basophilic phenotype of atopic asthma.